Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773734 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 352
- Enrollment target
NCT00773734 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 352 participants.
The verdict
NCT00773734, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 352 participants
- Enrollment target
Study Summary
The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
Interventions
- DRUG Placebo
- DRUG Apremilast 30mg
- DRUG Apremilast 20mg
- DRUG Apremilast 30 mg
- DRUG Apremilast 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2008-09-01 |
| Est. Completion | 2015-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00773734
The ClinicalTrials.gov registry entry for NCT00773734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00773734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00773734 about?
NCT00773734 is a clinical study titled "Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)". The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
What is the current status of trial NCT00773734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 352 participants. The study started on 2008-09-01. Estimated completion is 2015-05-20.
What interventions are being tested in trial NCT00773734?
The interventions under investigation include: Placebo (DRUG), Apremilast 30mg (DRUG), Apremilast 20mg (DRUG), Apremilast 30 mg (DRUG), Apremilast 10mg (DRUG).
Who is sponsoring clinical trial NCT00773734?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.